Eli Lilly and Company $LLY Shares Purchased by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 21.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 43,514 shares of the company’s stock after purchasing an additional 7,542 shares during the quarter. Eli Lilly and Company comprises 1.0% of Dana Investment Advisors Inc.’s portfolio, making the stock its 15th largest holding. Dana Investment Advisors Inc.’s holdings in Eli Lilly and Company were worth $33,201,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of LLY. Insight Advisors LLC PA lifted its holdings in Eli Lilly and Company by 21.0% in the 3rd quarter. Insight Advisors LLC PA now owns 1,493 shares of the company’s stock valued at $1,141,000 after acquiring an additional 259 shares during the last quarter. Cvfg LLC raised its holdings in shares of Eli Lilly and Company by 4.4% in the 3rd quarter. Cvfg LLC now owns 4,465 shares of the company’s stock worth $3,407,000 after purchasing an additional 187 shares in the last quarter. Portland Global Advisors LLC lifted its stake in Eli Lilly and Company by 17.3% during the third quarter. Portland Global Advisors LLC now owns 880 shares of the company’s stock valued at $671,000 after purchasing an additional 130 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 4.5% during the third quarter. EverSource Wealth Advisors LLC now owns 6,396 shares of the company’s stock valued at $4,880,000 after purchasing an additional 276 shares during the last quarter. Finally, Nkcfo LLC bought a new stake in Eli Lilly and Company during the third quarter worth approximately $1,526,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial: Novo Nordisk’s next‑gen obesity drug failed to demonstrate non‑inferiority to Lilly’s tirzepatide in an 84‑week study, boosting expectations that Lilly will maintain or grow market share in the lucrative weight‑loss category. Novo Nordisk’s obesity drug falls short against Eli Lilly’s (Reuters)
• Positive Sentiment: FDA label expansion & product launch: The FDA approved a four‑dose multi‑use KwikPen for Zepbound; Lilly announced immediate launch and said the self‑pay price option remains the same, which may lower friction for patients and improve adherence/retention. Eli Lilly’s Zepbound Gets FDA OK for Multi‑Dose Pen (WSJ)
• Positive Sentiment: Commercial positioning: Lilly’s KwikPen offers a month of doses in one device and a $299 self‑pay option, which investors view as a retention and convenience win that could support longer customer lifecycles and stable revenue per patient. Zepbound now available in multi‑dose KwikPen (PR Newswire)
• Positive Sentiment: Pipeline and combo data: Lilly reported positive data showing Taltz plus Zepbound outperformed Taltz alone in overweight/obese psoriasis patients — broadens use cases and supports incremental label/market opportunities. LLY expands pipeline with positive trial data (InsiderMonkey)
• Positive Sentiment: Institutional demand and analyst support: Reports show hedge funds and ETFs increased exposure to mega‑caps including Lilly, and some firms have recently raised price targets — supporting momentum and liquidity. Hedge funds’ Eli Lilly buying spree (Benzinga)
• Negative Sentiment: Insider/large‑holder selling flagged by data aggregators — large institutional rebalancing (e.g., Lilly Endowment sales reported) shows notable share dispositions in recent quarters; investors may watch whether selling continues or is one‑time reallocation. QuiverQuant note on insider & institutional activity

Eli Lilly and Company Stock Performance

LLY stock opened at $1,057.38 on Tuesday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The stock has a market cap of $997.49 billion, a P/E ratio of 46.07, a P/E/G ratio of 1.17 and a beta of 0.39. The firm has a 50 day simple moving average of $1,054.73 and a 200 day simple moving average of $920.78. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the prior year, the business earned $5.32 EPS. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a dividend of $1.73 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is 30.15%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 2nd. HSBC reaffirmed a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Leerink Partners increased their price target on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a research report on Thursday, February 5th. Argus boosted their price objective on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Finally, Wolfe Research upped their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,228.54.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.